drugset / Trial / NCT05085639
GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)
RandomizedSingle-groupSingle-blindPrevention
Summary
Phase I study of the safety, tolerability and immunogenicity of GLS-5310 DNA vaccine against SARS-CoV-2 (COVID-19)
Timeline
- Start
- 2021-11
- Primary completion
- 2022-04
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GLS-5130 | Unknown | 1.2 mg | Intrathecal |
| Subject | GLS-5130 | Unknown | 2.4 mg | Intrathecal |